Microalbuminuria sensitive near‐infrared AIE probe for point‐of‐care evaluating kidney diseases

Abstract

Urinary microalbumin (mALB) serves as an exceptionally sensitive indicator for the early detection of kidney damage, playing a pivotal role in identifying chronic renal failure and kidney lesions in individuals. Nevertheless, the current fluorescent methodologies for point‐of‐care (POC) diagnosis of mALB in real urine still exhibit suboptimal performance. Herein, the development and synthesis of QM‐N2, an albumin‐activated near‐infrared (NIR) aggregation‐induced emission (AIE) fluorescent probe, are presented. The strategic incorporation and positioning of quaternary ammonium salts within the quinoline‐malononitrile (QM) scaffold significantly influence solubility and luminescence characteristics. Specifically, the quaternary ammonium salt‐free variant, QM‐OH, and the quaternary ammonium salt integrated at the donor function group (DFG) site, QM‐N1, display limited solubility in aqueous solutions while demonstrating a distinct fluorescence signal. Conversely, the incorporation of quaternary ammonium salt at the conformational functional group (CFG) site in QM‐N2 imparts superior dispersibility in water and reduces the initial fluorescence. Furthermore, the integration of a well‐defined D‐π‐A structure within QM‐N2 enables itself with near‐infrared emission, which is crucial for mitigating interference from autofluorescence present in urine samples. Upon interaction with albumin, QM‐N2 forms a tight bond with the IIA site of the subdomain of human serum albumin (HSA), inducing alterations in protein configuration and constraining the intrinsic motion of fluorescent molecules. This interaction induces fluorescence, facilitating the sensitive detection of trace albumin. Ultimately, QM‐N2 is applied for POC testing of mALB using portable equipment, particularly in the diagnosis of mALB‐related diseases, notably chronic renal failure. This positioning underscores its potential as an ideal candidate for self‐health measurement at home or in community hospitals.

Anti-cancer drug axitinib: a unique tautomerism-induced dual-emissive probe for protein analysis

“…In contrast, fluorescencebased analytical methods have emerged as promising alternatives for detecting HSA due to their simplified procedures, rapid response times, and enhanced selectivity. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] However, most reported probes enable HSA detection based on changes in a single emission peak, which can be easily influenced by variations in analyte-independent factors, such as excitation source, photobleaching, and probe concentration. [26][27][28] Alternatively, a ratiometric fluorescent probe can provide a response signal dependent on the ratio of two emissions, rather than relying solely on a single emission.…”